Epicrispr Biotechnologies Reports Promising Phase 1/2 Data Showing Increased Muscle Volume with EPI-321 in Patients with Facioscapulohumeral Muscular Dystrophy
Epicrispr Biotechnologies, a clinical-stage biotechnology company focused on developing epigenetic therapies, has announced encouraging interim results from its ongoing Phase 1/2 first-in-human clinical trial evaluating EPI-321 in patients with facioscapulohumeral muscular dystrophy (FSHD). The new findings provide what the company believes is the first reported clinical evidence that an investigational therapy has increased muscle volume in individuals with FSHD, a rare and progressive genetic muscle disorder that currently has no approved disease-modifying treatments.
The interim data suggest that EPI-321 not only demonstrated a favorable safety profile but also showed evidence of biological activity consistent with its intended mechanism of action. Imaging analyses revealed measurable increases in lean muscle volume among evaluable participants, while supporting biomarker data indicated suppression of disease-related molecular activity.
Although the study remains in its early stages and additional follow-up is needed, the findings represent an important milestone in the development of epigenetic therapies for neuromuscular diseases.
Addressing a Disease with No Approved Therapies
Facioscapulohumeral muscular dystrophy is one of the most common inherited muscular dystrophies, affecting approximately one in every 8,000 to 20,000 individuals worldwide.
The disease is characterized by progressive muscle weakness and degeneration, initially affecting muscles of the face, shoulders, and upper arms before gradually involving other muscle groups throughout the body.
As the disease advances, many patients experience increasing difficulty with walking, climbing stairs, lifting objects, maintaining posture, and performing routine daily activities. In more severe cases, loss of mobility and independence may occur.
Despite decades of research, there are currently no approved therapies capable of altering the underlying disease process in FSHD. Existing treatment approaches primarily focus on symptom management, rehabilitation, and supportive care.
Against this backdrop, the development of therapies targeting the molecular cause of the disease has become a major priority within the neuromuscular research community.
Interim Data from the Ongoing Phase 1/2 Trial
The newly released results are based on data collected through May 12, 2026, from Epicrispr’s ongoing open-label Phase 1/2 clinical trial evaluating EPI-321 in adults with FSHD.
At the time of the interim analysis, nine patients had received treatment across two dose levels.
Six participants were enrolled in the first dose cohort and received a single intravenous infusion of EPI-321 at 2 × 10¹³ vector genomes per kilogram.
An additional three patients received a higher dose of 4 × 10¹³ vector genomes per kilogram in the second dose cohort.
The primary objectives of the study include evaluating safety, tolerability, biological activity, and preliminary evidence of clinical efficacy following administration of the investigational therapy.
Favorable Safety Profile Observed
One of the most encouraging aspects of the interim analysis is the safety profile observed thus far.
According to Epicrispr, no serious adverse events had been reported among treated participants as of the data cutoff.
The favorable tolerability observed during the early stages of the trial supports continued clinical development and enrollment into additional dose cohorts and longer-term follow-up.
As with all early-stage gene therapy studies, investigators will continue monitoring participants over an extended period to evaluate both short-term and long-term safety outcomes.
First Evidence of Increased Muscle Volume
Perhaps the most significant finding from the interim analysis was the observation of measurable gains in lean muscle volume among the first three evaluable patients treated at the target dose.
At the six-month assessment, all three participants demonstrated increases in muscle volume compared with their baseline measurements.
On average, patients experienced an increase of approximately 370 milliliters of lean muscle volume, equivalent to nearly 0.8 pounds of additional muscle mass.
Individual improvements ranged from approximately 0.5 pounds to 1.3 pounds of lean muscle.
In some individual muscles, investigators observed increases in lean muscle volume of as much as 15 percent.
According to the company, these findings may represent the first clinical evidence showing that a therapeutic intervention can increase muscle volume in individuals living with FSHD.
Contrasting Historical Disease Progression
The MRI findings are particularly noteworthy because they differ substantially from the natural progression typically observed in patients with FSHD.
Historically, individuals enrolled in FSHD clinical studies—including several recent Phase 3 trials—have generally experienced progressive muscle loss over time as the disease advances.
Instead of continued muscle degeneration, all evaluable participants treated with EPI-321 demonstrated measurable increases in muscle volume after six months.
Epicrispr believes this contrast may indicate that the investigational therapy is influencing the underlying biological mechanisms responsible for ongoing muscle deterioration.
The company had previously reported encouraging improvements in muscle strength and functional performance three months after treatment in these same participants.
The newly reported imaging findings provide additional evidence that these earlier functional improvements may be accompanied by measurable structural changes within muscle tissue.
Targeting the Genetic Cause of FSHD
Unlike conventional therapies that primarily address symptoms, EPI-321 is designed to directly target the genetic driver responsible for FSHD.
The therapy utilizes Epicrispr’s proprietary Gene Expression Modulation System (GEMS) platform, an epigenetic technology developed to regulate disease-causing genes without permanently altering the underlying DNA sequence.
Specifically, EPI-321 is engineered to silence DUX4, a gene that is abnormally activated in individuals with FSHD.
Excessive DUX4 activity triggers a cascade of molecular events that contribute to muscle inflammation, degeneration, and progressive weakness.
By suppressing DUX4 expression through epigenetic regulation, EPI-321 aims to provide durable protection against continued muscle damage following a single intravenous administration.
The company believes this approach may offer long-lasting therapeutic benefit while avoiding permanent modifications to the patient’s genome.
Biomarker Data Support Biological Activity
The MRI findings were reinforced by additional biological evidence collected during the study.
Investigators observed favorable reductions in a novel circulating cell-free DNA biomarker associated with activity of the DUX4 pathway.
According to Epicrispr, reductions in this biomarker provide complementary evidence that EPI-321 is successfully engaging its intended molecular target.
The biomarker changes were directionally consistent with the observed increases in muscle volume as well as previously reported improvements in muscle strength and physical function.
Together, the imaging, biomarker, and functional data provide multiple independent measures supporting the therapy’s biological activity.
Company Describes Results as a Scientific Milestone
Amber Salzman, Ph.D., Chief Executive Officer of Epicrispr Biotechnologies, described the interim findings as an important breakthrough for both the FSHD community and the broader field of epigenetic medicine.
She noted that, for the first time, investigators have observed clinical evidence suggesting that suppression of the genetic driver of FSHD may lead to measurable increases in muscle volume.
According to Salzman, the consistency among imaging data, molecular biomarkers, and functional outcomes strengthens confidence that EPI-321 may have the potential to meaningfully alter the progression of the disease rather than simply managing symptoms.
She emphasized that these encouraging early results support continued clinical development of the therapy.
Investigators Encourage Continued Evaluation
Russell Butterfield, MD, Principal Investigator of the study and Associate Professor of Pediatrics and Neurology at the University of Utah, highlighted the substantial unmet need faced by patients living with FSHD.
He noted that progressive muscle loss affects nearly every aspect of daily life, limiting mobility, independence, and overall quality of life.
According to Dr. Butterfield, physicians have historically had few opportunities to influence the underlying course of the disease.
While emphasizing that the current findings remain preliminary and require longer-term follow-up, he said the observed increases in lean muscle volume are encouraging and suggest that EPI-321 may be addressing the biological mechanisms driving disease progression.
If confirmed in larger studies, such effects could ultimately translate into meaningful clinical benefits for patients.
Advanced MRI Technology Provides Detailed Assessment
The muscle volume analyses were performed in collaboration with Springbok Analytics, whose artificial intelligence-powered imaging platform enables detailed quantitative assessment of muscle tissue throughout the body.
Using whole-body MRI scans combined with AI-based analysis, researchers were able to objectively measure changes across as many as 140 individual muscles in each participant.
This advanced imaging approach provides considerably greater precision than traditional clinical assessments alone, allowing investigators to detect subtle treatment-related changes in muscle composition.
Silvia Blemker, Ph.D., Chief Scientific Officer of Springbok Analytics, said the consistency of the MRI findings across all evaluable participants was particularly striking given the expected natural progression of FSHD.
She noted that quantitative whole-body imaging may become an increasingly valuable tool for evaluating emerging therapies targeting neuromuscular diseases.
Study Continues as Development Advances
The ongoing Phase 1/2 clinical trial (NCT06907875) continues to evaluate EPI-321 in adults diagnosed with facioscapulohumeral muscular dystrophy.
Researchers will continue assessing safety, tolerability, biological activity, and early efficacy as additional participants complete follow-up.
Epicrispr plans to present updated clinical findings during the World Muscle Society Annual Congress in September 2026, providing a more comprehensive evaluation of patient outcomes.
The company expects to complete the primary portion of the Phase 1/2 study in mid-2027, after which additional analyses will help determine the therapy’s future clinical development pathway.
The interim results reported by Epicrispr Biotechnologies represent an encouraging step forward in the search for disease-modifying treatments for facioscapulohumeral muscular dystrophy. By demonstrating favorable safety, measurable increases in lean muscle volume, supporting biomarker changes, and earlier improvements in muscle function, EPI-321 has generated early evidence that epigenetic regulation of the DUX4 gene may influence the underlying biology of this debilitating disease.
While additional patients, longer follow-up, and larger clinical studies will be necessary to confirm these findings, the data provide an important proof of concept for Epicrispr’s Gene Expression Modulation System platform. For patients living with FSHD—who currently have no approved disease-modifying therapies—the continued development of EPI-321 offers renewed hope that targeting the genetic drivers of disease may eventually transform treatment and improve long-term muscle function and quality of life.
About Facioscapulohumeral Muscular Dystrophy (FSHD)
Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common forms of muscular dystrophy, affecting an estimated 870,000 people worldwide. FSHD is a progressive genetic neuromuscular disease characterized by the gradual weakening and loss of skeletal muscle, often beginning in the face, shoulders, and upper arms before progressing to other parts of the body. The disease is caused by aberrant expression of DUX4, a gene that is normally silenced in healthy muscle tissue but becomes activated in individuals with FSHD, leading to muscle damage, inflammation, and progressive muscle degeneration. There are currently no approved disease-modifying therapies for FSHD.
About Epicrispr Biotechnologies
Epicrispr Biotechnologies is a biotechnology company pioneering gene-modulating therapies, leading with treatments for neuromuscular diseases. The company’s proprietary Gene Expression Modulation System (GEMS) enables precise and durable epigenetic modulation of gene expression, unlocking first-in-class treatments for previously untreatable conditions. Epicrispr’s lead program, EPI-321 is in clinical trials for FSHD, and the company is advancing additional gene-modulating therapies.
